Watch BOLD. Know when insiders buy.
One email the day a filing lands. Free.
Work order
24
FLAG · insiders 47, shorts 0
Insiders, 90 days
−$54K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $65.3MP/E —DIV YIELD —FCF YIELD -86.90%REV TTM —NET INCOME −$64MNET CASH —52W 1.05 – 3.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$24.4M | −$23.7M | — | -1.06 | −$21M | $38K | −$21M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$14.5M | −$13.6M | — | -0.60 | −$15M | $8K | −$15M | May 8 |
| Q4 2025 · Dec 31derived | — | — | — | −$14M | −$12.9M | — | -0.57 | −$10.1M | $424K | −$10.5M | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | −$15.1M | −$13.9M | — | -0.62 | −$10.2M | $15K | −$10.2M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$17.1M | −$15.7M | — | -0.70 | −$11.8M | $48K | −$11.9M | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$17.3M | −$15.8M | — | -0.71 | −$14.5M | $59K | −$14.6M | May 8 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.3M | −$16.4M | — | -0.63 | −$15.6M | $466K | −$16M | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$18.7M | −$16.5M | — | -0.74 | −$13.3M | $483K | −$13.7M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$19.4M | −$17M | — | -0.77 | −$16.2M | $1.5M | −$17.7M | Aug 5 |
| Q1 2024 · Mar 31 | — | — | — | −$16.9M | −$15.4M | — | -12.27 | −$15.8M | $83K | −$15.9M | May 9 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.8M | −$12.1M | — | -9.76 | −$11.7M | $268K | −$12M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$15M | −$13.2M | — | -10.71 | −$12.2M | $151K | −$12.3M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$63.6M | −$58.2M | — | -2.60 | −$46.7M | $546K | −$47.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$73.3M | −$65.4M | — | -3.85 | −$60.8M | $2.5M | −$63.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$54.8M | −$49.4M | — | -40.65 | −$46.9M | $633K | −$47.5M | — | — |
Every number comes from Boundless Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.